{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:41:27Z","timestamp":1793313687865,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jbo.2025.100668","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:54:09Z","timestamp":1741031649000},"page":"100668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives"],"prefix":"10.1016","volume":"51","author":[{"given":"Oxana","family":"Lungu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Toscani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.jbo.2025.100668_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/cells11152308","article-title":"Bone disease in multiple myeloma: biologic and clinical implications","volume":"11","author":"Bernstein","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.jbo.2025.100668_b0010","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00774-023-01403-4","article-title":"Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents","volume":"41","author":"Teramachi","year":"2023","journal-title":"J. Bone Miner. Metab."},{"issue":"11","key":"10.1016\/j.jbo.2025.100668_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113267","article-title":"Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability","volume":"12","author":"Chiu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0025","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12740","article-title":"The biology of normal bone remodelling","volume":"26","author":"Katsimbri","year":"2017","journal-title":"Eur. J. Cancer Care (Engl.)"},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbo.2025.100668_b0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jdsr.2021.08.006","article-title":"Pathogenesis and treatment of multiple myeloma bone disease","volume":"57","author":"Hiasa","year":"2021","journal-title":"Jpn Dent Sci Rev"},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2011.23","article-title":"Advances in osteoclast biology: old findings and new insights from mouse models","volume":"7","author":"Edwards","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6937","key":"10.1016\/j.jbo.2025.100668_b0045","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0050","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2141.1999.01491.x","article-title":"Human osteoclasts derive from CD14-positive monocytes","volume":"106","author":"Massey","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","article-title":"Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families","volume":"20","author":"Suda","year":"1999","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0060","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4110\/in.2018.18.e8","article-title":"Regulation of osteoclast differentiation by cytokine networks","volume":"18","author":"Amarasekara","year":"2018","journal-title":"Immune Netw."},{"issue":"9","key":"10.1016\/j.jbo.2025.100668_b0065","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20051150","article-title":"Autoamplification of NFATc1 expression determines its essential role in bone homeostasis","volume":"202","author":"Asagiri","year":"2005","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1210\/me.2007-0237","article-title":"NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP)","volume":"22","author":"Kim","year":"2008","journal-title":"Mol. Endocrinol."},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0075","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/jbmr.1575","article-title":"Osteoclast stimulatory transmembrane protein and dendritic cell-specific transmembrane protein cooperatively modulate cell-cell fusion to form osteoclasts and foreign body giant cells","volume":"27","author":"Miyamoto","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"14","key":"10.1016\/j.jbo.2025.100668_b0080","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1128\/MCB.00077-12","article-title":"c-Src links a RANK\/alphavbeta3 integrin complex to the osteoclast cytoskeleton","volume":"32","author":"Izawa","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jbo.2025.100668_b0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bone.2017.12.021","article-title":"Metabolic properties of the osteoclast","volume":"115","author":"Arnett","year":"2018","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.jbo.2025.100668_b0090","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2174\/1389450121666200925150446","article-title":"The regulatory role of rho GTPases and their substrates in osteoclastogenesis","volume":"22","author":"Gao","year":"2021","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0095","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1006\/cyto.1997.0277","article-title":"Cytokines, growth factors and osteoclasts","volume":"10","author":"Heymann","year":"1998","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/ijms17030349","article-title":"MicroRNAs in osteoclastogenesis and function: potential therapeutic targets for osteoporosis","volume":"17","author":"Ji","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2025.100668_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115507","article-title":"Epigenetic and transcriptional regulation of osteoclastogenesis in the pathogenesis of skeletal diseases: a systematic review","volume":"138","author":"Sharma","year":"2020","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0110","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12761","article-title":"Mechanisms of bone destruction in multiple myeloma","volume":"26","author":"Terpos","year":"2017","journal-title":"Eur. J. Cancer Care (Engl.)"},{"issue":"11","key":"10.1016\/j.jbo.2025.100668_b0115","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.ejca.2005.12.025","article-title":"The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions","volume":"42","author":"Mitsiades","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2010.05.036","article-title":"TGF-beta-related mechanisms of bone destruction in multiple myeloma","volume":"48","author":"Matsumoto","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2025.100668_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117503","article-title":"IGF-1 promotes multiple myeloma progression through PI3K\/Akt-mediated epithelial-mesenchymal transition","volume":"249","author":"Peng","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-018-0666-5","article-title":"Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis","volume":"11","author":"Petrusca","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0135","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3324\/haematol.2016.153841","article-title":"IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts","volume":"102","author":"Bolzoni","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cei.12751","article-title":"Interleukin-21 induces migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis","volume":"184","author":"Xing","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0145","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1038\/s41467-023-39769-8","article-title":"The checkpoint inhibitor PD-1H\/VISTA controls osteoclast-mediated multiple myeloma bone disease","volume":"14","author":"Fu","year":"2023","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.jbo.2025.100668_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136651","article-title":"Osteoblast differentiation and signaling: established concepts and emerging topics","volume":"22","author":"Ponzetti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jbo.2025.100668_b0160","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bone.2014.07.028","article-title":"Skeletal (stromal) stem cells: an update on intracellular signaling pathways controlling osteoblast differentiation","volume":"70","author":"Abdallah","year":"2015","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.jbo.2025.100668_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071694","article-title":"Regulation of proliferation, differentiation and functions of osteoblasts by Runx2","volume":"20","author":"Komori","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2025.100668_b0170","article-title":"Two-sided function of osteopontin during osteoblast differentiation","author":"Mardiyantoro","year":"2024","journal-title":"J. Biochem."},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0175","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00418-018-1640-6","article-title":"Runx2, an inducer of osteoblast and chondrocyte differentiation","volume":"149","author":"Komori","year":"2018","journal-title":"Histochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/hmbci-2016-0009","article-title":"The \u201csoft\u201d side of the bone: unveiling its endocrine functions","volume":"28","author":"Cappariello","year":"2016","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.jbo.2025.100668_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.abb.2014.05.003","article-title":"Osteoblast and osteocyte: games without frontiers","volume":"561","author":"Capulli","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41421-024-00689-6","article-title":"Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0195","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/ncb2139","article-title":"CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells","volume":"13","author":"Wei","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.jbo.2025.100668_b0200","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/jcb.24144","article-title":"MicroRNAs miR-96, miR-124, and miR-199a regulate gene expression in human bone marrow-derived mesenchymal stem cells","volume":"113","author":"Laine","year":"2012","journal-title":"J. Cell. Biochem."},{"issue":"33","key":"10.1016\/j.jbo.2025.100668_b0205","doi-asserted-by":"crossref","first-page":"25221","DOI":"10.1074\/jbc.M110.116137","article-title":"miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop","volume":"285","author":"Kapinas","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.jbo.2025.100668_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107355","article-title":"Growth and dormancy control of myeloma cells by mesenchymal stem cells","volume":"133","author":"Mehdi","year":"2023","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bone.2010.06.016","article-title":"Osteoblast function in myeloma","volume":"48","author":"Roodman","year":"2011","journal-title":"Bone"},{"issue":"14","key":"10.1016\/j.jbo.2025.100668_b0225","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2025.100668_b0230","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garcia-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"26","key":"10.1016\/j.jbo.2025.100668_b0235","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease","volume":"118","author":"D'Souza","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2025.100668_b0240","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fendo.2018.00344","article-title":"XRK3F2 inhibition of p62-ZZ domain signaling rescues myeloma-induced GFI1-driven epigenetic repression of the Runx2 gene in pre-osteoblasts to overcome differentiation suppression","volume":"9","author":"Adamik","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0245","first-page":"322","article-title":"Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics, World","volume":"6","author":"Garcia-Gomez","year":"2014","journal-title":"J. Stem Cells"},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0250","first-page":"174","article-title":"Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma","volume":"89","author":"Standal","year":"2004","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0255","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0260","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo","volume":"111","author":"Edwards","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009870","article-title":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0270","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0275","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0280","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1078-0432.CCR-13-1657","article-title":"Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease","volume":"20","author":"Garcia-Gomez","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2025.100668_b0285","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286554","article-title":"Myeloma cell growth suppression by osteoblast-derived extracellular vesicles: the creation of a non-permissive niche for myeloma cells by bone-forming osteoblasts","author":"Kim","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0290","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00223-013-9774-y","article-title":"Osteocyte-driven bone remodeling","volume":"94","author":"Bellido","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.jbo.2025.100668_b0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41413-020-0099-y","article-title":"Molecular mechanosensors in osteocytes","volume":"8","author":"Qin","year":"2020","journal-title":"Bone Res."},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0300","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11914-017-0373-0","article-title":"Osteocyte mechanobiology","volume":"15","author":"Uda","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0305","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00774-020-01176-0","article-title":"Sclerostin: from bench to bedside","volume":"39","author":"Tanaka","year":"2021","journal-title":"J. Bone Miner. Metab."},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0315","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11914-020-00564-9","article-title":"Osteocyte-mediated translation of mechanical stimuli to cellular signaling and its role in bone and non-bone-related clinical complications","volume":"18","author":"Yan","year":"2020","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.jbo.2025.100668_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116136","article-title":"Osteocyte calcium signaling \u2013 a potential translator of mechanical load to mechanobiology","volume":"153","author":"Lewis","year":"2021","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.jbo.2025.100668_b0325","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/jbmr.1646","article-title":"Matrix metalloproteinase-13 is required for osteocytic perilacunar remodeling and maintains bone fracture resistance","volume":"27","author":"Tang","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2025.100668_b0330","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev-physiol-021119-034332","article-title":"The osteocyte: new insights","volume":"82","author":"Robling","year":"2020","journal-title":"Annu. Rev. Physiol."},{"issue":"11","key":"10.1016\/j.jbo.2025.100668_b0335","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ng1905","article-title":"Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism","volume":"38","author":"Feng","year":"2006","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0340","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11914-016-0297-0","article-title":"The role of osteocytes in age-related bone loss","volume":"14","author":"Jilka","year":"2016","journal-title":"Curr. Osteoporos. Rep."},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0345","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","article-title":"Role of osteocytes in multiple myeloma bone disease","volume":"8","author":"Delgado-Calle","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.jbo.2025.100668_b0350","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286484","article-title":"Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma","author":"Anloague","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0355","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2025.100668_b0360","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3389\/fimmu.2018.02467","article-title":"Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy","volume":"9","author":"Toscani","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0365","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0370","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jbmr.2741","article-title":"The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors","volume":"31","author":"Toscani","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2025.100668_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117236","article-title":"3D osteocyte lacunar morphometry of human bone biopsies with high resolution microCT: from monoclonal gammopathy to newly diagnosed multiple myeloma","volume":"189","author":"Moreno-Jimenez","year":"2024","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.jbo.2025.100668_b0380","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae093","article-title":"Evidence for peri-lacunar remodeling and altered osteocyte lacuno-canalicular network in mouse models of myeloma-induced bone disease","volume":"8","author":"Evans","year":"2024","journal-title":"JBMR Plus"},{"issue":"24","key":"10.1016\/j.jbo.2025.100668_b0385","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbo.2025.100668_b0390","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-019-0178-8","article-title":"Osteoimmunology: evolving concepts in bone-immune interactions in health and disease","volume":"19","author":"Tsukasaki","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"22","key":"10.1016\/j.jbo.2025.100668_b0395","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3303.3303","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.jbo.2025.100668_b0400","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1182\/blood-2019-130462","article-title":"Osteoclast-induced immunosuppression occurs through dysregulation of immune checkpoint axes in multiple myeloma","volume":"134","author":"Mukaihara","year":"2019","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.jbo.2025.100668_b0405","doi-asserted-by":"crossref","first-page":"56598","DOI":"10.18632\/oncotarget.17896","article-title":"Expression of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0410","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-21-0310","article-title":"Runx2 deficiency in osteoblasts promotes myeloma resistance to bortezomib by increasing TSP-1-dependent TGFbeta1 activation and suppressing immunity in bone marrow","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0415","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jbo.2025.100668_b0420","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL)","volume":"32","author":"Giuliani","year":"2004","journal-title":"Exp. Hematol."},{"issue":"12","key":"10.1016\/j.jbo.2025.100668_b0425","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor","volume":"186","author":"Wong","year":"1997","journal-title":"J. Exp. Med."},{"issue":"51","key":"10.1016\/j.jbo.2025.100668_b0430","doi-asserted-by":"crossref","first-page":"34120","DOI":"10.1074\/jbc.273.51.34120","article-title":"The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily","volume":"273","author":"Galibert","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"43","key":"10.1016\/j.jbo.2025.100668_b0435","doi-asserted-by":"crossref","first-page":"41147","DOI":"10.1074\/jbc.M205063200","article-title":"Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator","volume":"277","author":"Ishida","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0440","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","article-title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts","volume":"3","author":"Takayanagi","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.jbo.2025.100668_b0445","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.jbo.2025.100668_b0450","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbo.2025.100668_b0455","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/sj.leu.2404875","article-title":"Mouse models and the RANKL\/OPG axis in myeloma bone disease","volume":"21","author":"Dingli","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0460","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajpath.2015.11.003","article-title":"Inhibition of transforming growth factor-beta activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma","volume":"186","author":"Lu","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.jbo.2025.100668_b0465","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/ijc.22845","article-title":"Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival","volume":"121","author":"Menu","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0470","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s42003-024-06918-8","article-title":"Aberrant NSUN2-mediated m5C modification of exosomal LncRNA MALAT1 induced RANKL-mediated bone destruction in multiple myeloma","volume":"7","author":"Yu","year":"2024","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0475","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0480","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4161\/org.4.2.5851","article-title":"Wnt signal transduction pathways","volume":"4","author":"Komiya","year":"2008","journal-title":"Organogenesis"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0485","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41375-019-0404-1","article-title":"Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options","volume":"33","author":"van Andel","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2025.100668_b0490","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-cellbio-120319-023657","article-title":"Cell biology of canonical Wnt signaling","volume":"37","author":"Albrecht","year":"2021","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0495","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1083\/jcb.200701083","article-title":"Cdc42 and noncanonical Wnt signal transduction pathways cooperate to promote cell polarity","volume":"178","author":"Schlessinger","year":"2007","journal-title":"J. Cell Biol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0500","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/leu.2012.190","article-title":"Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a\/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells","volume":"27","author":"Bolzoni","year":"2013","journal-title":"Leukemia"},{"issue":"3\u20134","key":"10.1016\/j.jbo.2025.100668_b0505","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ceca.2005.06.022","article-title":"Wnt and calcium signaling: beta-catenin-independent pathways","volume":"38","author":"Kohn","year":"2005","journal-title":"Cell Calcium"},{"issue":"7","key":"10.1016\/j.jbo.2025.100668_b0510","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0168-9525(00)02028-X","article-title":"The Wnt\/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape","volume":"16","author":"Kuhl","year":"2000","journal-title":"Trends Genet."},{"issue":"10","key":"10.1016\/j.jbo.2025.100668_b0515","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/sj.onc.1206239","article-title":"Wnt signaling in B-cell neoplasia","volume":"22","author":"Qiang","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0520","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0525","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2010-09-308171","article-title":"Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model","volume":"117","author":"Gunn","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jbo.2025.100668_b0530","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1073\/pnas.0610299104","article-title":"Targeting the beta-catenin\/TCF transcriptional complex in the treatment of multiple myeloma","volume":"104","author":"Sukhdeo","year":"2007","journal-title":"PNAS"},{"issue":"16","key":"10.1016\/j.jbo.2025.100668_b0535","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Derksen","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.jbo.2025.100668_b0540","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.jbo.2025.100668_b0545","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fendo.2018.00788","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","volume":"9","author":"Harmer","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0550","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S8756-3282(00)00263-5","article-title":"Interleukin-6 modulates trabecular and endochondral bone turnover in the nude mouse by stimulating osteoclast differentiation","volume":"26","author":"Rozen","year":"2000","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0555","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"Raje","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.jbo.2025.100668_b0560","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0565","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jbo.2025.100668_b0570","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0575","first-page":"73","article-title":"Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts","volume":"4","author":"Nierste","year":"2014","journal-title":"Am. J. Blood Res."},{"issue":"7","key":"10.1016\/j.jbo.2025.100668_b0580","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jbo.2025.100668_b0585","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J. Exp. Med."},{"issue":"26","key":"10.1016\/j.jbo.2025.100668_b0590","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0595","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.jbo.2025.100668_b0600","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/jbmr.3859","article-title":"TGFbeta inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model","volume":"34","author":"Green","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2025.100668_b0605","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1059715","article-title":"Targeting TGF-beta signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction","volume":"10","author":"Rana","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.jbo.2025.100668_b0610","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1007\/s00277-024-05843-4","article-title":"TGF-beta: an active participant in the immune and metabolic microenvironment of multiple myeloma: TGF-beta in the microenvironment of multiple myeloma","volume":"103","author":"Xue","year":"2024","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0615","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1385\/MO:19:3:133","article-title":"Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma","volume":"19","author":"Jurisic","year":"2002","journal-title":"Med. Oncol."},{"key":"10.1016\/j.jbo.2025.100668_b0620","article-title":"Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma","volume":"5","author":"Rizzieri","year":"2019","journal-title":"J. Cancer Metastasis Treat."},{"issue":"30","key":"10.1016\/j.jbo.2025.100668_b0625","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/onc.2015.464","article-title":"Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax","volume":"35","author":"Bajpai","year":"2016","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0630","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2025.100668_b0635","doi-asserted-by":"crossref","unstructured":"Y. Yu, H. Newman, L. Shen, D. Sharma, G. Hu, A.J. Mirando, H. Zhang, E. Knudsen, G.F. Zhang, M.J. Hilton, C.M. Karner, Glutamine metabolism regulates proliferation and lineage allocation in skeletal stem cells, Cell Metab 29(4) (2019) 966-978 e4.","DOI":"10.1016\/j.cmet.2019.01.016"},{"issue":"10","key":"10.1016\/j.jbo.2025.100668_b0640","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1038\/s44319-024-00255-x","article-title":"Glutaminolysis provides nucleotides and amino acids to regulate osteoclast differentiation in mice","volume":"25","author":"Hu","year":"2024","journal-title":"EMBO Rep."},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0645","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41419-024-06475-2","article-title":"IL-17 promotes osteoclast-induced bone loss by regulating glutamine-dependent energy metabolism","volume":"15","author":"Peng","year":"2024","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.jbo.2025.100668_b0650","doi-asserted-by":"crossref","first-page":"285","DOI":"10.30802\/AALAS-CM-21-000012","article-title":"Relationships between Slc1a5 and osteoclastogenesis","volume":"71","author":"Tsumura","year":"2021","journal-title":"Comp. Med."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0655","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164508","article-title":"Glucose- and glutamine-dependent bioenergetics sensitize bone mechanoresponse after unloading by modulating osteocyte calcium dynamics","volume":"133","author":"Liu","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.jbo.2025.100668_b0660","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0665","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0670","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.jbo.2025.100668_b0675","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100668_b0680","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00223-017-0349-1","article-title":"The proteasome and myeloma-associated bone disease","volume":"102","author":"Accardi","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.jbo.2025.100668_b0685","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jbspin.2007.05.004","article-title":"Influence of RANKL inhibition on immune system in the treatment of bone diseases","volume":"75","author":"Fouque-Aubert","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbo.2025.100668_b0690","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fonc.2013.00329","article-title":"Effects of RANKL-targeted therapy in immunity and cancer","volume":"3","author":"Cheng","year":"2014","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.jbo.2025.100668_b0695","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2011-08-376236","article-title":"Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma","volume":"119","author":"Koduru","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jbo.2025.100668_b0700","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:20:43Z","timestamp":1742376043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137425000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":140,"alternative-id":["S2212137425000090"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100668","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100668"}}